Future of Treating Melanoma

Source: OncLive, September 2019

Jeffrey S. Weber, MD, PhD: This has been extremely informative. But before we end this discussion, I’d like to get some final thoughts from each of the panelists. Dr Jason Luke?

Jason J. Luke, MD, FACP: I think this year’s ASCO [American Society of Clinical Oncology Annual Meeting] really identifies how we have made a tremendous amount of progress yet have a long way to go. We need to be judicious in thinking through that as our prior conversations outline. It just really needs to be highlighted that clinical trial participation is still essential. Because while we made significant progress, it’s not clear yet what the next step is. And without continuing to push the field forward, we’re not going to make that progress. Especially patients who are in the refractory disease setting. They need to be referred for clinical trials because we really just don’t know what to do with them yet.

Jeffrey S. Weber, MD, PhD: Are you worried that we have more trials than patients?